1. Modeling the long-term efficacy of neratinib in the extended adjuvant setting for women with HER2+/HR+ early stage breast cancer (ESBC). (March 2019) Authors: Doan, Q.; Lalla, D.; Yao, B.; Danese, M.; Barnett, B.; Crown, J. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Population effectiveness model of the consequences of recurrences following treatment with trastuzumab among women with HER2+ early stage breast cancer in the United States. (March 2019) Authors: Doan, Q.; Martin, M.; Lalla, D.; Halperin, M.; Barnett, B.; Bryce, R.; Danese, M.; Moy, B. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗